In a landmark move for US pharmaceutical manufacturing, Fresenius Kabi and Phlow Corp. have announced a first-of-its-kind collaboration to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA-designated essential medicine that has repeatedly found itself on national drug shortage lists. The partnership signals a decisive shift in how the United States approaches critical medicine supply security, and it carries significant implications for API manufacturers, finished-dose producers, and contract development and manufacturing organizations (CDMOs) worldwide.
Epinephrine injection is one of the most critical emergency medicines in global healthcare. Listed as an essential medicine by both the US Food and Drug Administration (WHO) and the World Health Organization, it is the frontline treatment for anaphylaxis and cardiac arrest. Yet despite its clinical importance, the United States has long depended on foreign sources for the active pharmaceutical ingredient, creating a persistent vulnerability in the supply chain.
This dependency has manifested in repeated shortage episodes over the past decade. Supply disruptions — driven by manufacturing quality issues at overseas API facilities, regulatory delays, and geopolitical friction — have periodically left US hospitals scrambling for epinephrine stock. The Fresenius Kabi–Phlow collaboration directly addresses this structural weakness by bringing API production back onto American soil.
Under the agreement, Phlow Corp., a US-based pharmaceutical CDMO, will manufacture epinephrine API domestically. Phlow has already completed a manufacturing validation campaign and filed a Drug Master File (DMF) with the FDA, positioning itself as the emerging domestic source for this critical active ingredient.
Fresenius Kabi, meanwhile, will handle the downstream formulation and finished-dose production. The company has been manufacturing epinephrine finished doses in the US for some time, but until now, the API itself has been sourced from overseas suppliers. This collaboration fills that critical gap, creating what the two companies describe as the first fully domestic, end-to-end supply chain for a medicine frequently at risk of shortage.
Eric Edwards, M.D., Ph.D., CEO of Phlow Corp., testified before the United States Congress about the importance of onshoring essential medicine manufacturing. His company's partnership with Fresenius Kabi represents the commercial realization of that vision.
Fresenius Kabi has invested nearly $1 billion since 2017 to expand and modernize its US pharmaceutical production and distribution capabilities. More than 70% of units shipped by Fresenius Kabi in the US are drugs listed on the FDA's Essential Medicines List, underscoring the company's strategic focus on critical-care and hospital products.
The epinephrine produced through this collaboration could become available to US hospitals as early as 2027, pending regulatory approvals. This relatively aggressive timeline reflects the maturity of Phlow's API manufacturing capabilities and Fresenius Kabi's existing finished-dose infrastructure.
This collaboration is more than a bilateral deal — it is a signal to the global API supply chain that the US market is entering a new era of supply chain reshoring. Several dynamics are converging to accelerate this trend:
Legislative tailwinds. The US government has been steadily increasing pressure to reduce dependence on foreign API sources, particularly for essential medicines. Programs like Phlow's CDMO operations are receiving federal support, and the regulatory environment is increasingly favorable to domestic API production.
Quality control advantages. Domestic API manufacturing eliminates the complexities of cross-border regulatory harmonization and reduces the risk of quality failures at facilities that may face less direct FDA oversight. For hospitals and finished-dose manufacturers, a domestic API source translates into more predictable supply and fewer compliance surprises.
Cost recalibration. While overseas API production has traditionally enjoyed a cost advantage, rising labor costs in Asia, increasing logistics expenses, and the growing cost of quality assurance are narrowing that gap. For essential medicines with established demand, the total cost of domestic production — factoring in supply reliability and regulatory simplicity — is becoming increasingly competitive.
For CDMOs eyeing the US market, the Fresenius Kabi–Phlow model provides a template: partner with an established finished-dose manufacturer to offer a vertically integrated domestic supply. This model reduces risk for both parties and creates a compelling value proposition for hospital procurement teams under pressure to ensure supply continuity.
Intermediates and fine chemicals suppliers should also take note. As domestic API production scales up, there will be increased demand for US-sourced or US-qualified starting materials, intermediates, and reagents. Suppliers who can demonstrate reliable, high-quality domestic supply chains will be well-positioned to capture this emerging market.
The Fresenius Kabi–Phlow epinephrine collaboration is not the end of the story — it is the beginning. Both companies have indicated that the model is designed to be scalable to other essential medicines. If successful, it could catalyze a wave of similar partnerships across the US pharmaceutical landscape, reshaping API sourcing strategies for years to come.
For API and intermediates suppliers worldwide, the message is clear: the US market is moving toward domestic supply chain resilience. Those who adapt — whether by establishing US manufacturing presence, forging partnerships with domestic CDMOs, or demonstrating exceptional quality and reliability — will thrive in this evolving landscape.
